FDA to reconvene on treatment for Alzheimer’s psychosis in June

The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
Nuplazid (pimavanserin, Acadia Pharmaceuticals) is a selective serotonin inverse agonist and antagonist that targets 5-HT2A receptors, which are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine, histamine, muscarinic or adrenergic receptors.
The FDA will meet June 17 to review the application.
“We

The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
Nuplazid (pimavanserin, Acadia Pharmaceuticals) is a selective serotonin inverse agonist and antagonist that targets 5-HT2A receptors, which are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine, histamine, muscarinic or adrenergic receptors.
The FDA will meet June 17 to review the application.
“We